Fresenius SE & Co. KGaA (FREN) Stock Price & Analysis
FREN Stock Chart & Stats
- Day’s Range
- MXN 791.93 - MXN 791.93
- 52-Week Range
- MXN 791.93 - MXN 792.00
- Previous Close
- MXN 791.93
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 607.64B
- Enterprise Value
- MXN 35.58B
- Total Cash (Recent Filing)
- MXN 1.72B
- Total Debt (Recent Filing)
- MXN 11.84B
- Price to Earnings (P/E)
- 18.3
- Beta
- 0.03
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- 19.25
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.73%
Bulls Say, Bears Say
Bulls Say
Profit Recovery
The sharp recovery in net income, alongside higher revenue and a stronger net margin, indicates that operating performance has materially improved. If maintained, this earnings base should support reinvestment, strengthen resilience, and provide a more durable platform for performance over the next several quarters.
Improved Balance Sheet
Debt reduction and equity growth have materially improved leverage from earlier years, giving Fresenius a steadier capital base. Lower debt-to-equity should reduce financial strain and improve flexibility for investment, deleveraging, and navigating changes in profitability or reimbursement.
Healthcare Platform
The combination of hospital services, essential medical products, and dialysis exposure gives Fresenius several healthcare earnings pillars. This breadth links the company to recurring care needs and chronic disease management, supporting business durability beyond any single product or operating segment.
Bears Say
Debt Burden
Although leverage has improved, the absolute debt balance remains substantial relative to Fresenius’s healthcare services model. This can constrain capital allocation and leave less flexibility if profitability, utilization, or reimbursement trends weaken, making sustained deleveraging important to long-term stability.
Moderate Cash Conversion
Positive cash generation is a strength, but only moderate conversion of earnings into free cash flow reduces the company’s ability to fund investment and debt reduction internally. The low operating-cash-flow-to-debt measure makes continued cash discipline important for financial flexibility.
Margin Pressure
The weaker gross margin versus earlier years and the recent EBITDA margin decline suggest that cost pressure is limiting operating leverage. Even with improved net profitability, persistent margin erosion could restrict earnings growth and make the recovery more dependent on revenue expansion.
Fresenius SE & Co. KGaA News
FREN FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
What is Fresenius SE & Co. KGaA’s market cap?
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Is Fresenius SE & Co. KGaA overvalued?
Does Fresenius SE & Co. KGaA pay dividends?
What is Fresenius SE & Co. KGaA’s EPS estimate?
How many shares outstanding does Fresenius SE & Co. KGaA have?
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
What is the TipRanks Smart Score and how is it calculated?
Fresenius SE & Co. KGaA Stock Smart Score
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Michael Sen
- Employees
- 178,394
- Website
- www.fresenius.com
- Address
- Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, HE, 61352, DE
Fresenius SE & Co. KGaA (FREN) Earnings & Revenues
FREN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 0 | 13 |
| Technical Analysis | 0 | 0 | 2 |
| Moving Averages | 1 | 0 | 11 |
